[A20-49] Daratumumab (newly diagnosed multiple myeloma, stem cell transplant unsuitable) - Addendum to Commission A20-14
Last updated 20.08.2020
Project no.:
A20-49
Commission:
Commission awarded on 20.08.2020 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Cancer
Adults with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant
Under consideration of the data subsequently submitted, the positive effects prevail; now hint of minor added benefit
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
| Project no. | Title | Status |
|---|---|---|
| A20-14 | Daratumumab (multiple myeloma) - Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
2020-08-20: G-BA decision was published.